• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经蝶窦垂体腺瘤切除术治疗生长激素、催乳素和促肾上腺皮质激素分泌型垂体瘤:125例患者的疗效分析

Transsphenoidal adenomectomy for GH-, PRL- and ACTH-secreting pituitary tumours: outcome analysis in a series of 125 patients.

作者信息

Esposito V, Santoro A, Minniti G, Salvati M, Innocenzi G, Lanzetta G, Cantore G

机构信息

Department of Neurological Sciences, IRCCS-NEUROMED, University of Rome La Sapienza, Parco Tecnologico, Via Atinense, I-86077 Pozzilli (IS), Italy.

出版信息

Neurol Sci. 2004 Dec;25(5):251-6. doi: 10.1007/s10072-004-0351-z.

DOI:10.1007/s10072-004-0351-z
PMID:15624082
Abstract

Transsphenoidal surgery (TSS) is a well recognised treatment for secreting pituitary adenomas, however a very wide variation of clinical outcomes and recurrence rates has been reported, depending on the different criteria used to define the cure. We reported the clinical outcome of a large series of patients operated on for a secreting pituitary adenoma according to the most recent stringent criteria of biochemical remission nowadays accepted. One hundred and twenty-five consecutive patients with a secreting pituitary adenoma (42 PRL-, 67 GH- and 16 ACTH-secreting adenomas) who were operated on by the two same neurosurgeons were considered for the study. Biochemical remission of disease was achieved in 56% of patients; 78% for patients with microadenoma and 47% for patients with macroadenomas, respectively. No cases of mortality or major immediate postoperative complications were observed. Tumour size, high hormone levels and dural invasion were significantly correlated to a poor surgical outcome. The recurrence rates ranged between 0 and 24%, being higher for PRL-secreting tumours. In conclusion, TSS is safe and effective in secreting pituitary tumours. It is still the first treatment for GH- and ACTH-secreting adenomas, whereas in patients with prolactinomas, surgery should be reserved for cases of resistance or intolerance to dopamine agonists.

摘要

经蝶窦手术(TSS)是公认的分泌性垂体腺瘤的治疗方法,然而,根据用于定义治愈的不同标准,临床结果和复发率的差异很大。我们根据目前公认的最新严格生化缓解标准,报告了一大系列接受分泌性垂体腺瘤手术患者的临床结果。本研究纳入了由两位相同神经外科医生手术治疗的125例连续分泌性垂体腺瘤患者(42例泌乳素分泌型、67例生长激素分泌型和16例促肾上腺皮质激素分泌型腺瘤)。56%的患者实现了疾病的生化缓解;微腺瘤患者和大腺瘤患者的缓解率分别为78%和47%。未观察到死亡病例或严重的术后即刻并发症。肿瘤大小、高激素水平和硬膜侵犯与手术效果不佳显著相关。复发率在0%至24%之间,泌乳素分泌型肿瘤的复发率更高。总之,经蝶窦手术在分泌性垂体肿瘤中是安全有效的。它仍然是生长激素和促肾上腺皮质激素分泌型腺瘤的首选治疗方法,而对于泌乳素瘤患者,手术应保留用于对多巴胺激动剂耐药或不耐受的病例。

相似文献

1
Transsphenoidal adenomectomy for GH-, PRL- and ACTH-secreting pituitary tumours: outcome analysis in a series of 125 patients.经蝶窦垂体腺瘤切除术治疗生长激素、催乳素和促肾上腺皮质激素分泌型垂体瘤:125例患者的疗效分析
Neurol Sci. 2004 Dec;25(5):251-6. doi: 10.1007/s10072-004-0351-z.
2
Biochemical remission and recurrence rate of secreting pituitary adenomas after transsphenoidal adenomectomy: long-term endocrinologic follow-up results.经蝶窦腺瘤切除术后分泌性垂体腺瘤的生化缓解及复发率:长期内分泌随访结果
Surg Neurol. 2007 Nov;68(5):513-8; discussion 518. doi: 10.1016/j.surneu.2007.05.057.
3
Endocrinological outcome following first time transsphenoidal surgery for GH-, ACTH-, and PRL-secreting pituitary adenomas.首次经蝶窦手术治疗生长激素、促肾上腺皮质激素和泌乳素分泌型垂体腺瘤后的内分泌学结果。
Acta Neurochir (Wien). 2002 Jun;144(6):555-61; discussion 561. doi: 10.1007/s00701-002-0938-1.
4
A prospective analysis of 151 cases of patients with acromegaly operated by one neurosurgeon: a follow-up of more than 23 years.一位神经外科医生对151例肢端肥大症患者进行手术的前瞻性分析:超过23年的随访。
Surg Neurol. 2006 Jul;66(1):26-31; discussion 31. doi: 10.1016/j.surneu.2005.11.063.
5
The use of neuronavigation in transnasal transsphenoidal pituitary surgery.神经导航在经鼻蝶窦垂体手术中的应用。
Zentralbl Neurochir. 2005 Aug;66(3):126-32; discussion 132. doi: 10.1055/s-2005-836602.
6
Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria.生长激素分泌型垂体腺瘤的外科治疗:一项采用现代缓解标准的疗效研究。
J Clin Endocrinol Metab. 2001 Sep;86(9):4072-7. doi: 10.1210/jcem.86.9.7819.
7
Outcome of transsphenoidal surgery for Cushing's disease: a high remission rate in ACTH-secreting macroadenomas.库欣病经蝶窦手术的结果:促肾上腺皮质激素分泌型大腺瘤的缓解率高。
Clin Neurol Neurosurg. 2009 Jun;111(5):442-9. doi: 10.1016/j.clineuro.2008.12.011. Epub 2009 Feb 5.
8
Endoscopic transsphenoidal treatment in recurrent and residual pituitary adenomas--first experience.内镜经蝶窦治疗复发性和残留性垂体腺瘤——初步经验
Minim Invasive Neurosurg. 2006 Feb;49(1):10-4. doi: 10.1055/s-2006-932126.
9
Complications of transsphenoidal surgery in patients with pituitary adenoma: experience at a single centre.垂体腺瘤患者经蝶窦手术的并发症:单中心经验
Acta Neurochir (Wien). 2007;149(9):877-85; discussion 885-6. doi: 10.1007/s00701-007-1244-8. Epub 2007 Jul 9.
10
Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases.促甲状腺激素分泌型垂体腺瘤的临床病理特征及治疗结果:一项90例的单中心研究
J Neurosurg. 2014 Dec;121(6):1462-73. doi: 10.3171/2014.7.JNS1471. Epub 2014 Sep 19.

引用本文的文献

1
Radiation Therapy for Recurrent or Residual Pituitary Macroadenoma Invading Extrasellar Structures.放疗治疗侵犯鞍外结构的复发性或残留垂体大腺瘤。
Yonsei Med J. 2022 Dec;63(12):1059-1068. doi: 10.3349/ymj.2022.0323.
2
Costs and Its Determinants in Pituitary Tumour Surgery.垂体瘤手术的成本及其决定因素。
Front Endocrinol (Lausanne). 2022 Jul 7;13:905019. doi: 10.3389/fendo.2022.905019. eCollection 2022.
3
Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis.
在内镜时代,多巴胺激动剂仍是催乳素瘤的首选治疗方法吗?一项系统评价和荟萃分析。
Chin Neurosurg J. 2022 Apr 8;8(1):9. doi: 10.1186/s41016-022-00277-1.
4
The combination of N-ammonia and C-methionine in differentiation of residual/recurrent pituitary adenoma from the pituitary gland remnant after trans-sphenoidal Adenomectomy.经蝶窦腺瘤切除术后,N-氨和C-蛋氨酸联合用于鉴别残留/复发性垂体腺瘤与垂体残余组织。
BMC Cancer. 2021 Jul 20;21(1):837. doi: 10.1186/s12885-021-08574-1.
5
Endoscopic surgical treatment of Cushing's disease: A single-center experience of cauterization of peritumoral tissues.库欣病的内镜手术治疗:瘤周组织烧灼术的单中心经验
Exp Ther Med. 2019 Dec;18(6):4420-4426. doi: 10.3892/etm.2019.8075. Epub 2019 Oct 3.
6
The experience with transsphenoidal surgery and its importance to outcomes.经蝶窦手术的经验及其对结果的重要性。
Pituitary. 2018 Oct;21(5):545-555. doi: 10.1007/s11102-018-0904-4.
7
Preoperative Computed Tomography (CT) Evaluation of Anatomical Abnormalities in Endonasal Transsphenoidal Approach in Pituitary Adenoma.经鼻蝶窦入路垂体瘤术前计算机断层扫描(CT)评估的解剖学异常。
Med Sci Monit. 2018 Mar 2;24:1268-1275. doi: 10.12659/msm.904402.
8
Microsurgical versus endoscopic transsphenoidal resection for acromegaly: a systematic review of outcomes and complications.经蝶窦显微手术与内镜手术治疗肢端肥大症的系统评价:疗效与并发症分析
Acta Neurochir (Wien). 2017 Nov;159(11):2193-2207. doi: 10.1007/s00701-017-3318-6. Epub 2017 Sep 14.
9
Different Volumetric Measurement Methods for Pituitary Adenomas and Their Crucial Clinical Significance.不同的垂体腺瘤体积测量方法及其关键的临床意义。
Sci Rep. 2017 Jan 18;7:40792. doi: 10.1038/srep40792.
10
The surgical treatment of acromegaly.肢端肥大症的外科治疗
Pituitary. 2017 Feb;20(1):76-83. doi: 10.1007/s11102-016-0765-7.